The present invention relates to combination therapy comprising a DPP4inhibitor and an SGLT inhibitor. Thecombination of the present invention leads to increase plasma GLP-1 level andthe combination is useful for prevention or treatmentof conditions such as diabetes and diseases related to diabetes.